Evidence map›Paper›PMID 25875290›Full record

ArticlePloS one2015

Sevoflurane inhibits nuclear factor-κB activation in lipopolysaccharide-induced acute inflammatory lung injury via toll-like receptor 4 signaling.

Xi Jia Sun, Xiao Qian Li, Xiao Long Wang, Wen Fei Tan, Jun Ke Wang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in cellular and infection microbiology · 2020
    Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Volatile Anesthetics and Immunity.Immunological investigations · 2017
    Review
  16. Article
  17. Perioperative "remote" acute lung injury: recent update.Journal of biomedical research · 2017
    Article
  18. Ketamine effect on HMGB1 and TLR4 expression in rats with acute lung injury.International journal of clinical and experimental pathology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xi Jia SunDepartment of Anesthesiology, First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning, China.
Xiao Qian LiDepartment of Anesthesiology, First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning, China.
Xiao Long WangDepartment of Anesthesiology, First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning, China.
Wen Fei TanDepartment of Anesthesiology, First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning, China.
Jun Ke WangDepartment of Anesthesiology, First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning, China.
China Medical University · CNFirst Hospital of China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfection is a common cause of acute lung injury (ALI). This study was aimed to explore whether Toll-like receptors 4 (TLR4) of airway smooth muscle cells (ASMCs) play a role in lipopolysaccharide (LPS)-induced airway hyperresponsiveness and potential mechanisms.

methodsIn vivo: A sensitizing dose of LPS (50 µg) was administered i.p. to female mice before anesthesia with either 3% sevoflurane or phenobarbital i.p. After stabilization, the mice were challenged with 5 µg of intratracheal LPS to mimic inflammatory attack. The effects of sevoflurane were assessed by measurement of airway responsiveness to methacholine, histological examination, and IL-1, IL-6, TNF-α levels in bronchoalveolar lavage fluid (BALF). Protein and gene expression of TLR4 and NF-κB were also assessed. In vitro: After pre-sensitization of ASMCs and ASM segments for 24h, levels of TLR4 and NF-κB proteins in cultured ASMCs were measured after continuous LPS exposure for 1, 3, 5, 12 and 24h in presence or absence of sevoflurane. Constrictor and relaxant responsiveness of ASM was measured 24 h afterwards.

resultsThe mRNA and protein levels of NF-κB and TLR4 in ASM were increased and maintained at high level after LPS challenge throughout 24h observation period, both in vivo and in vitro. Sevoflurane reduced LPS-induced airway hyperresponsiveness, lung inflammatory cell infiltration and proinflammatory cytokines release in BALF as well as maximal isometric contractile force of ASM segments to acetylcholine, but it increased maximal relaxation response to isoproterenol. Treatment with specific NF-κB inhibitor produced similar protections as sevoflurane, including decreased expressions of TLR4 and NF-κB in cultured ASMCs and improved pharmacodynamic responsiveness of ASM to ACh and isoproterenol.

conclusionsThis study demonstrates the crucial role of TLR4 activation in ASMCs during ALI in response to LPS. Sevoflurane exerts direct relaxant and anti-inflammatory effects in vivo and in vitro via inhibition of TLR4/NF-κB pathway.

Indexed as

AcetylcholineAcute Lung InjuryAnimalsAnti-Inflammatory Agents, Non-SteroidalBronchoalveolar Lavage FluidBronchodilator AgentsFemaleGene Expression RegulationInterleukin-1Interleukin-6IsoproterenolLipopolysaccharidesLungMethyl EthersMiceMice, Inbred C57BL3-(4-methylphenylsulfonyl)-2-propenenitrileAcetylcholineAnti-Inflammatory Agents, Non-SteroidalBronchodilator AgentsInterleukin-1Interleukin-6interleukin-6, mouseIsoproterenolLipopolysaccharidesMethyl EthersMuscle Relaxants, CentralNF-kappa BNitrilesSevofluraneSulfonesTlr4 protein, mouseToll-Like Receptor 4Tumor Necrosis Factor-alphaVasodilator Agents

Identifiers

PMID25875290
PMCPMC4397052
OpenAlexW2061425075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.